HIGHLIGHTS OF PRESCRIBING INFORMATION 

 

These highlights do not include all the information needed to use RHOPRESSA® safely and effectively. See full prescribing information for RHOPRESSA®. 

RHOPRESSA® (netarsudil ophthalmic solution) 0.02%, for topical ophthalmic use 

Initial U.S. Approval:  2017

 

INDICATIONS AND USAGE 

 

RHOPRESSA® (netarsudil ophthalmic solution) 0.02% is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. (1) 

 

DOSAGE AND ADMINISTRATION 

 

One drop into the affected eye(s) once daily in the evening. (2) 

 

DOSAGE FORMS AND STRENGTHS 

 

Ophthalmic solution containing 0.2 mg/mL of netarsudil. (3) 

 

CONTRAINDICATIONS 

 

None. (4) 

 

ADVERSE REACTIONS 

 

The most common adverse reaction is conjunctival hyperemia (53%). Other common adverse reactions, approximately 20% include: corneal verticillata, instillation site pain, and conjunctival hemorrhage. (6.1) 

To report SUSPECTED ADVERSE REACTIONS, contact Aerie Pharmaceuticals, Inc. at 1‑855‑740-1924, or FDA at 

1-800-FDA-1088 or www.fda.gov/medwatch. 

 

See 17 for PATIENT COUNSELING INFORMATION.

 

Revised: 12/2017

 

FULL PRESCRIBING INFORMATION: CONTENTS* 

 

1 INDICATIONS AND USAGE  

 

2 DOSAGE AND ADMINISTRATION  

 

3 DOSAGE FORMS AND STRENGTHS  

 

4 CONTRAINDICATIONS  

 

5 WARNINGS AND PRECAUTIONS  

 

5.1 Bacterial Keratitis  

 

5.2 Use with Contact Lenses  

 

6 ADVERSE REACTIONS  

 

6.1 Clinical Trials Experience  

 

8 USE IN SPECIFIC POPULATIONS  

 

8.1 Pregnancy  

 

8.2 Lactation  

 

8.4 Pediatric Use  

 

8.5 Geriatric Use  

 

11 DESCRIPTION  

 

12 CLINICAL PHARMACOLOGY  

 

12.1 Mechanism of Action  

 

12.3 Pharmacokinetics  

 

13 NONCLINICAL TOXICOLOGY  

 

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility  

 

14 CLINICAL STUDIES  

 

16 HOW SUPPLIED/STORAGE AND HANDLING  

 

17 PATIENT COUNSELING INFORMATION  

* Sections or subsections omitted from the full prescribing information are not listed.  

1 INDICATIONS AND USAGE 

 

RHOPRESSA (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

 

2 DOSAGE AND ADMINISTRATION 

 

The recommended dosage is one drop in the affected eye(s) once daily in the evening.